Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development stewardship of therapeutic candidates from early discovery to commercial implementation.
The Company’s anti-infective product portfolio includes three clinical stage monoclonal antibodies and three additional preclinical anti-infective drug candidates. This suite of anti-infective monoclonal antibodies is highly differentiated from conventional antibiotics, effective against all antibiotic resistant strains which the mAbs are directed against, and offers opportunities to profoundly impact current approaches to infection control.
Our products target infectious diseases that have a significant impact on life expectancy and address acute medical needs including:
AR-301 (SalvecinTM) is a fully human monoclonal IgG1 antibody that specifically targets S. aureus alpha-toxin, a toxic protein secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA). AR-301 protects against alpha-toxin dependent destruction, preserving the human immune cells.
AR-105 (Aerucin®) is a broadly active, fully human IgG1 monoclonal antibody targeted against P. aeruginosa alginate, a widely distributed cell surface polysaccharide involved in surface adhesion, biofilm formation, and protection against the human immune system. Aerucin exhibits a broad recognition to diverse, unrelated P. aeruginosa clinical isolates due to the ubiquitous nature of the alginate surface polysaccharide.
AR-101 (AerumabTM) is a highly specific monoclonal antibody targeted against P. aeruginosa lipopolysaccharide serotype O11, which accounts for ~22% of all P. aeruginosa hospital-acquired infections worldwide. Binding of AR-101 to P. aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human phagocytes.
Complementing our current clinical pipeline, we have three additional drug candidates in preclinical development. AR-501 has broad bactericidal activity against Gram-negative and Gram-positive bacteria, including antibiotic-resistant strains. AR-201 is a human IgG1 mAb directed against the F-protein of respiratory syncytial virus (RSV). AR-401 is a mAb discovery program to treat infections caused by the Gram-negative bacterium Acinetobacter baumannii.
In virtually all infectious diseases, there is subset of disease-free individuals that are generating rare, potent, protective immune responses to even the most lethal pathogens. Human monoclonal antibodies are often the key protective components. Our discovery technology platform aims to find and transform these components into innovative therapies.